Close Menu


"I've been absolutely blown away by the microRNA field and the way it's blossomed," University of Massachusetts Medical School researcher and Nobel laureate Craig Mello said. "There is just one story after another [showing that] microRNAs … are very critical to many aspects of either disease or development."

IP Update: Dec 31, 2009


USPTO Publishes Five Patents, Twenty Patent Applications Related to RNAi

The firm reported no revenues for the quarter, but it anticipates revenues of between $2 million and $4 million in 2010 tied to sales of its microRNA-based tests.

According to Nobel laureate Craig Mello, RNAi for research applications "really is very reliable and it works very well. I think where it was over-hyped is this notion that you can just give a patient RNA and expect them to get better."

The company said that as a result of the planned divestiture, it will seek partners to co-develop and commercialize its miRNA-based diagnostics.

The company has exclusively licensed inventions related to the modulation of miR-146 and miR-155, key mediators of the inflammatory response.

Chris Earl, Corey Goodman, Evan Melrose

Miragen Therapeutics, which holds the rights to the discovery, is interested in seeing the work advance. But a company official said that development of a miRNA-targeting drug for ALS would likely only occur in earnest with a partner.

Papers of Note: Dec 10, 2009


RNAi-Related Papers Published November 2009

IP Update: Dec 10, 2009


USPTO Publishes One Patent, Ten Patent Applications Related to RNAi


Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.

Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.

Stat News reports some health tech startups are laying off or furloughing workers.

In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.